Drugs / Neo-RCC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07686744 | Sep 2026 → Jan 2029 expected | renal cell carcinoma | Jian Lin | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neo-RCC | “personalized neoantigen polyepitope peptide vaccine (Neo-RCC) individually designed and manufactured for each patient based on whole exome sequencing (WES) and transcriptome...” NCT07686744 ↗ |
| Modality | Vaccine | “personalized neoantigen polyepitope peptide vaccine” NCT07686744 ↗ |
| Route | Subcutaneous | “Administration is via subcutaneous injection at 4 anatomical sites (bilateral axilla and bilateral groin)” NCT07686744 ↗ |